Manal F. Abdelmalek - Concepedia

Author

Manal F. Abdelmalek

Also Known As

Abdel Kader, Abdelmalek, Manal F., Elena Reynoso, G Biasco, Helen Te, M ABDELMALEK, M Abdelmalek, M F. Abdelmalek, M. Abdelmalek, M. F. Abdelmalek

346

Publications

42.7K

Citations

H-Index

134

Concepts

All Affiliations

Duke University Virginia Commonwealth University University of California San Diego Duke Medical Center Pinnacle Clinical Research

About

Manal F. Abdelmalek is an author at Duke University specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	71	15.9K
2	Health Sciences	25	30	7.4K
3	Public Health	3	3	312
4	Engineering	2	2	194
5	Applied Physiology	1	1	14

Manal F. Abdelmalek

145

Publications

29.3K

Citations

H-Index

Page 1

	Year	Citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Hepatology Evidence-based MedicinePathologyFatty Liver DiseaseObesityMetabolic Syndrome	2023	2.5K
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal, The Lancet HepatologyMedicineLiver PhysiologyPathologyPlacebo-controlled Trial	2014	2.2K
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, Hepatology	2023	2K
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, New England Journal of Medicine	2024	1.4K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Vlad Ratziu, Stephen A. Harrison, Sven Francque, Gastroenterology	2016	993
Fructose consumption as a risk factor for non-alcoholic fatty liver disease Xiaosen Ouyang, Pietro Cirillo, Yuri Y. Sautin, Journal of Hepatology ObesityMetabolic SyndromeNutritionMetabolic Associated SteatohepatitisHepatology	2008	851
Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver Disease Manal F. Abdelmalek, Ayako Suzuki, Cynthia D. Guy, Hepatology	2010	755
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH Sven Francque, Pierre Bédossa, Vlad Ratziu, New England Journal of Medicine	2021	655
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison, Hepatology	2017	646

Page 1